Dey Amit K, Groenendyk Jacob, Mehta Nehal N, Gourgari Evgenia
Section of Inflammation and Cardiometabolic Disease, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland.
Division of Pediatric Endocrinology, Georgetown University, Washington, District of Columbia.
Clin Cardiol. 2019 Mar;42(3):406-412. doi: 10.1002/clc.23152. Epub 2019 Feb 6.
Patients with type 2 diabetes have a significantly increased risk of cardiovascular disease (CVD) compared to the general population-with CVD accounting for two out of every three deaths in patients with diabetes. In 2008, the FDA suggested that CVD risk should be evaluated for any new antidiabetic therapy, leading to a multitude of large CVD outcome trials to assess CVD risk from these medications. Interestingly, several of these outcome trials with new novel antidiabetic therapies have demonstrated a clear and definite CVD advantage at mid-term follow up in high-risk patients with T2DM. In this review, we discuss two relatively new classes of diabetic drugs, sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists, and their efficacy in improving cardiovascular outcomes.
与普通人群相比，2型糖尿病患者患心血管疾病（CVD）的风险显著增加——CVD导致糖尿病患者每三例死亡中就有两例。2008年，美国食品药品监督管理局（FDA）建议，应对任何新型抗糖尿病疗法进行CVD风险评估，这导致了大量大型CVD结局试验，以评估这些药物的CVD风险。有趣的是，其中几项针对新型抗糖尿病疗法的结局试验表明，在2型糖尿病高危患者的中期随访中，这些疗法具有明确的CVD益处。在本综述中，我们讨论了两类相对较新的糖尿病药物，即钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽1激动剂，以及它们在改善心血管结局方面的疗效。
